+ HEALTH Aims Intramuscular fat (IMF) is increasingly recognized as a marker of ectopic adiposity and adverse cardiome…+ HEALTH Periapical lesions are challenging to detect on intraoral radiographs because of anatomical superimposition a…± HEALTH Ultrasound imaging is an indispensable diagnostic tool, yet its profound reliance on operator expertise inher…+ HEALTH Objectives We adapted the individualized polysocial risk score (iPsRS), a machine learning model originally d…± HEALTH Melioidosis is a life-threatening infectious disease caused by Burkholderia pseudomallei ( Bp ). Rapid diagno…+ HEALTH Classification is a core machine learning task, and ensemble voting methods are widely used to improve predic…+ CLIMATE Microplastic (MP) pollution poses escalating environmental risks, demanding efficient and reproducible tools…± HEALTH Medicinal chemistry sits at the center of modern drug discovery, yet translating molecular designs into appro…
TruaceTracing the truth around AIWednesday, August 26, 2026
Subscribe
TRV-2026-0831Certified recordPeer-reviewed

Multi-omics strategies for biomarker discovery and application in personalized oncology

Multi-omics strategies, integrating genomics, transcriptomics, proteomics, and metabolomics, have revolutionized biomarker discovery and enabled novel applications in personalized oncology. Despite rapid technological developments, a comprehensive synthesis addressing integration strategies, analytical workflows, and translational applications has been lacking. This review presents a comprehensive framework of multi-omics integration, encompassing workflows, analytical techniques, and computational tools for bot…

Health · The Trace — both readings · certified 2026-08-18 · v1 · article view · machine-readable

Current reading — gain

Integration of genomics, transcriptomics, proteomics and metabolomics using machine learning and deep learning has produced biomarker panels that support cancer diagnosis, prognosis and therapeutic decision-making.

Current reading — problem

Multi-omics biomarker approaches face persistent challenges in data heterogeneity, reproducibility, and clinical validation across diverse patient populations.

What this doesn’t fix

Clinical translation remains limited by data heterogeneity, reproducibility issues, and lack of validation across diverse patient populations.

Evidence

Reader signal

How should this claim be treated?

Cite this record

Truvace Impact Record TRV-2026-0831, v1: “Multi-omics strategies for biomarker discovery and application in personalized oncology.” Truvace, 2026-08-18. /record/TRV-2026-0831 (accessed at citation time). sha256 023dcc136a041e0a…

Calibration history

Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.

  1. Certifiedv1023dcc136a04…

    Certified into the record

Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-0831 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.